Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 285-287

  Issa, Nicolas C ^a,b,c   Marty, Francisco M ^a,b,c   Leblebjian, Houry ^b   Galar, Alicia ^a,c   Shea, Margaret M ^a   Antin, Joseph H ^b,c   Soiffer, Robert J ^b,c   Baden, Lindsey R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HSCT; Varicella zoster vaccine

Indexed keywords

ACICLOVIR; FAMCICLOVIR; GABAPENTIN; MEASLES MUMPS RUBELLA VACCINE; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HUMAN HERPES VIRUS 3 STRAIN OKA; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTHERPETIC NEURALGIA; SINGLE DRUG DOSE; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; WILD TYPE; YOUNG ADULT;

HSCT; VARICELLA-ZOSTER VACCINE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84893090976     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.013     Document Type: Article

References (23)

1. Asano-Mori Y., Kanda Y., Oshima K., et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008, 83:472-476.
2. Berman J.N., Wang M., Berry W., et al. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant 2006, 37:73-80.
3. Boeckh M., Kim H.W., Flowers M.E., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006, 107:1800-1805.
4. Han C.S., Miller W., Haake R., et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994, 13:277-283.
5. Locksley R.M., Flournoy N., Sullivan K.M., et al. Infection with varicella-zoster virus after marrow transplantation. JInfect Dis 1985, 152:1172-1181.
6. Sempere A., Sanz G.F., Senent L., et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992, 10:495-498.
7. Steer C.B., Szer J., Sasadeusz J., et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000, 25:657-664.
8. Su S.H., Martel-Laferriere V., Labbe A.C., et al. High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 17:1012-1017.
9. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007, 110:3071-3077.
10. Oxman M.N., Levin M.J., Johnson G.R., et al. Avaccine to prevent herpes zoster and postherpetic neuralgia in older adults. NEngl J Med 2005, 352:2271-2284.
11. Thomson K.J., Hart D.P., Banerjee L., et al. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:1065-1069.
12. Naidus E., Damon L., Schwartz B.S., et al. Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol 2012, 87:123-125.
13. Ljungman P., Cordonnier C., Einsele H., et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009, 44:521-526.
14. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
15. Schmader K.E., Levin M.J., Gnann J.W., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012, 54:922-928.
16. Galea S.A., Sweet A., Beninger P., et al. The safety profile of varicella vaccine: a 10-year review. JInfect Dis 2008, 197(Suppl 2):S165-S169.
17. Arbeter A.M., Starr S.E., Preblud S.R., et al. Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am J Dis Child 1984, 138:434-438.
18. Gershon A.A., Steinberg S.P. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. JInfect Dis 1990, 161:661-666.
19. Gershon A.A., Steinberg S.P., LaRussa P., et al. Immunization of healthy adults with live attenuated varicella vaccine. JInfect Dis 1988, 158:132-137.
20. Johnson C.E., Shurin P.A., Fattlar D., et al. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988, 81:512-518.
21. Weibel R.E., Kuter B.J., Neff B.J., et al. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 1985, 254:2435-2439.
22. Weibel R.E., Neff B.J., Kuter B.J., et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. NEngl J Med 1984, 310:1409-1415.
23. White C.J., Kuter B.J., Hildebrand C.S., et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991, 87:604-610.